Wes Kaupinen

Mr. Kaupinen brings more than 17 years of entrepreneurial life sciences experience as an operating executive and early stage investor, including having worked closely with several companies that have secured FDA approvals of novel treatments for high unmet indications. Prior to Palvella, Mr. Kaupinen served as Senior Vice President of Corporate Development and Commercialization at Insmed (NASDAQ: INSM), a global commercial stage biopharmaceutical company focused on rare diseases. Previously, Mr. Kaupinen was a Principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private investments, including recruiting new leadership to Insmed to execute on a rare disease strategy. Mr. Kaupinen has served as a board director or observer for more than ten companies, including leading Series A investments in Intact Vascular (backed by NEA, HIG, and Quaker) and TELA Bio (NASDAQ: TELA). Mr. Kaupinen earned an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. in Economics from The University of Virginia.